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Degree of disability, pain levels, muscle strength, and electromyographic 
function in patients with Hansen’s disease with common peroneal nerve damage
ABSTRACT
Introduction: This study evaluated the degree of disability, pain levels, muscle strength, 
and electromyographic function (RMS) in individuals with leprosy. Methods: We assessed 
29 individuals with leprosy showing common peroneal nerve damage and grade 1 or 2 
disability who were referred for physiotherapeutic treatment, as well as a control group of 19 
healthy participants without leprosy. All subjects underwent analyses of degree of disability, 
electromyographic tests, voluntary muscle force, and the Visual Analog Pain Scale. Results: 
McNemar’s test found higher levels of grade 2 of disability (∆ = 75.9%; p = 0.0001) among 
individuals with leprosy. The Mann-Whitney test showed greater pain levels (∆ = 5.0; p = 0.0001) 
in patients with leprosy who had less extension strength in the right and left extensor hallucis 
longus muscles (∆ = 1.28, p = 0.0001; ∆ = 1.55, p = 0.0001, respectively) and dorsiflexion of 
the right and left feet (∆ = 1.24, p = 0.0001; ∆ = 1.45, p = 0.0001, respectively) than control 
subjects. The Kruskal-Wallis test showed that the RMS score for dorsiflexion of the right 
(∆ = 181.66 m·s-2, p = 0.001) and left (∆ = 102.57m·s-2, p = 0.002) feet was lower in patients with 
leprosy than in control subjects, but intragroup comparisons showed no difference. Conclusions: 
Leprosy had a negative influence on all of the study variables, indicating the need for immediate 
physiotherapeutic intervention in individuals with leprosy. This investigation opens perspectives 
for future studies that analyze leprosy treatment with physical therapeutic intervention.
Keywords: Disability degree. Electromyography. Muscle strength. Pain. Peroneal nerve. 
Leprosy.
RESUMO
Introdução: O objetivo do estudo foi avaliar o grau de incapacidade, níveis de dor, força 
muscular e a função eletromiográfica (RMS) em indivíduos portadores de hanseníase. 
Métodos: A amostra foi composta de um grupo de 29 sujeitos portadores de hanseníase, 
apresentando lesão do nervo fibular comum e grau 1 ou 2 de incapacidade, com indicação ao 
tratamento fisioterapêutico, e um grupo controle de 19 indivíduos saudáveis, sem hanseníase. 
Os sujeitos foram submetidos à análise do grau de incapacidade, testes de eletromiografia, de 
força muscular voluntária e da Escala Visual Analógica (EVA) para a dor. Resultados: O teste 
de McNemar mostrou maior prevalência do grau dois de incapacidade (∆=75,9%; p=0,0001) 
entre os indivíduos com hanseníase. O teste de Mann-Whitney revelou maiores níveis de 
dor (∆=5,0; p=0,0001) nos pacientes com hanseníase apresentando menores níveis de força 
muscular da extensão do hálux direito e esquerdo (∆=1,28, p=0,0001; ∆=1,55, p=0,0001) 
e flexão dorsal do pé direito e esquerdo (∆=1,24, p=0,0001; ∆=1,45, p=0,0001) do que os 
indivíduos sem hanseníase. O teste de Kruskal-Wallis revelou que os valores do RMS da 
flexão dorsal dos pés direito (∆=181,66m.s-2, p=0,001) e esquerdo (∆=102,57m.s-2, p=0,002) 
apresentaram menores valores que o grupo controle em ambos os lados, mas as comparações 
intragrupos não mostraram diferenças. Conclusões: Conclui-se que a hanseníase altera todas 
as variáveis analisadas na pesquisa, indicando a necessidade de intervenção fisioterapêutica 
imediata nos sujeitos com Hanseníase. Esta investigação abre perspectivas de futuras pesquisas 
que analisem o tratamento da hanseníase com intervenção fisioterapêutica.
Palavras-chaves: Grau de incapacidade. Eletromiografia. Força muscular. Dor. Nervo fibular. 
Hanseníase. 
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Leprosy, a chronic infectious-contagious disease 
that is endemic in certain underdeveloped areas, is 
caused by a bacillus with an affinity for cutaneous 
cells and peripheral nerves. Nerve lesions are the 
most important cause of disabilities and give rise 
to the strong stigma associated with the disease1. 
If Mycobacterium leprae affected only the skin, the 
disease would not have such an important impact 
on public health2-4. Leprosy is characterized by 
clinical, histopathological, bacteriological, and 
immunological manifestations5, and it is primarily 
transmitted via the upper respiratory tract6.
This disease is one of the main preventable 
causes of disabilities in many developing countries, 
and is still present throughout the tropics and 
subtropics7. Brazil is among the most endemic 
countries for Hansen’s disease in the world, with 
37,610 new cases in 20098,9. Despite the reduction in 
prevalence from 1990-2009, leprosy remains a public 
health problem in Brazil10. If the neural damage is 
not treated early and adequately, disabilities and 
deformities in the lower limbs may occur due to 
sensitivity (areas with hypoesthesia or anesthesia), 
motor (muscle paresis/paralysis), and autonomic 
(dry skin) alterations in the areas innervated by the 
common peroneal and posterior tibial nerves. This 
may prompt the appearance of stigmatizing foot 
drop and plantar ulcers11,12. Chronic ulcers are more 
common in the lower extremities than in the upper 
extremities13, and they appear during treatment or 
after hospital discharge and sometimes precede the 
diagnosis of leprosy14. Triggering factors predispose 
their emergence, such as intermittent infections, 
vaccination, pregnancy and puerperium, iodine-
containing medication, and physical and emotional 
stress15.
Muscle strength levels and electromyographic 
signal response can decrease in patients with leprosy 
due to possible nerve damage caused by the leprosy 
bacillus16,17.
An examination of neural functions is necessary 
for adequate medical treatment, but there is still a 
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Delayed diagnosis and treatment are recognized risk factors for 
nerve damage and possible stigmatization. These often occur because 
infected individuals ignore symptoms such as reduced sensitivity and 
muscle strength or, depending on their culture, resort to traditional 
popular medicine for treatment19. When not diagnosed and treated 
early, leprosy is a chronic disease that can lead to physical incapacity20.
Shumin et al.21 and Cross22 point to polychemotherapy and 
early diagnosis as preventive measures, as well as standardized 
treatment and diagnosis, professional qualifications, and knowledge 
dissemination23. Neuropathy treatment is indicated when there 
is clear clinical activity with symptoms and signals of evolving 
neuropathy, neural loss, and reversible alterations24.
Accordingly, this study aimed to evaluate electromyographic 
function, degree of disability, muscle strength levels, and pain in 
individuals with leprosy.
Sample
We examined 29 subjects (19 men and 10 women) aged from 
16-82 years (mean: 47.55 ± 15.24 years; median: 47 years), diagnosed 
with leprosy, who were treated at a National Health System facility 
in the City of Teresina, Brazil. The patients who were referred 
for physical therapy treatment were invited to take part in this 
cross-sectional cohort study. All patients were treated at the Maria 
Imaculada Leprosy Foundation and Lineu Araújo Hospital, both 
reference centers for the diagnosis and treatment of leprosy. The 
control group was composed of 19 healthy volunteer participants 
(15 men and 4 women) aged from 21-65 years (mean: 36.00 ± 15.04 
years; median: 37 years). None of these individuals were leprosy 
patients nor did they exhibit any damage to the common peroneal 
nerve. 
The following inclusion criteria were adopted: leprosy patients 
with damage to the common peroneal nerve, treated or undergoing 
treatment with polychemotherapy, with grade 1 or 2 disability, and 
receiving physical therapy. Patients with no disability (grade 0) were 
excluded. Grade 0 indicates no functional disability; grade 1 indicates 
the loss of the protective sensation on the plantar surface; and 
grade 2 indicates the loss of the protective sensation on the plantar 
surface with other complications, e.g., ulcers and traumatic injuries, 
claws, foot drop, absorption, or contracture of the ankle25.
Diabetic and alcoholic individuals, due to the possible presence 
of peripheral nerve damage26, and those presenting with poliomyelitis 
and stroke sequelae were excluded from the study.
The subjects gave informed written consent, in accordance 
with resolution 196/96 of the National Health Council and the 
Declaration of Helsinki27. 
Data collection procedures
A simplified assessment of neural functions and complications 
and a formula for evaluating grades of disability standardized by 
the World Health Organization were used to classify grade 1 and 2 
disability28.
Pain was assessed using the Visual Analog Pain Scale (VAPS), whose 
score ranges from zero (absence of pain) to 10 (most severe pain)29.
Right and left foot sensitivity was evaluated using a set 
of 6 Semmes-Weinstein nylon monofilaments (Sorri Bauru 
Esthesiometer, Brazil) composed of 38-mm nylon threads of varying 
diameter. These produce different forces (0.05, 0.2, 2.0, 4.0, 10.0, 
and 300.0 g) at specific points on each lower limb, corresponding to 
the tibial, peroneal, and sural nerves, and are always compared with 
the contralateral side. Subjects keep their eyes closed to describe 
whether they feel anything, using the 2.0-g filament as a reference. 
If this filament is not detected, protective sensitivity has changed10,30.
Muscle strength was determined using voluntary muscle testing 
with the Oxford scale, which ranges from 5 to 0 (5 = strong, 4 = 
partial resistance, 3 = complete movement, 2 = partial movement, 
1 = contraction, and 0 = paralyzed)30,31. This test evaluates the 
extension strength of the right (RH) and left (LH) extensor hallucis 
longus muscles as well as the dorsiflexion of the right (RD) and 
left (LD) feet.
A Miotool 400 electromyograph (MIOTEC Equipamentos 
Biomédicos, Brazil) was used to obtain electromyographic data. 
This device is composed of a 4-channel system with a sampling 
frequency of 2000 Hz per channel, RAW filter, active sensors, and 
disposable Ag/AgCl electrodes (diameter: 30mm). Before the 
electromyographic signals were recorded from the anterior tibial 
muscle in the control and experimental groups, hair was removed 
from the area32. Surface electrodes were placed on the muscle belly 
at one-third of the distance between the fibular head and medial 
malleolus33,34. Individuals were placed in a sitting position in a 45-
cm high chair with a device that immobilized both feet, impeding 
dorsiflexion. They were asked to execute the same movement with 
maximum force, showing maximum voluntary isometric contraction 
(MVIC). Two series of 3 MVICs were performed. Each movement 
lasted 5 s, with a 3-s interval between them, and the best of these 
was selected. The subjects were allowed to rest for 3 min between 
series. Data were analyzed using the average root mean square 
(RMS) values.
Statistical analyses
Data were analyzed using Excel and SPSS 14.0 software and 
presented as mean, median, standard deviation, and minimum and 
maximum values. Normality and homogeneity of the variance were 
analyzed using the Shapiro-Wilk and Levene tests, respectively. 
McNemar’s test was applied to determine the frequency of degree of 
disability in the leprosy group (LG). Other variables were compared 
using Student’s t-test for independent samples or the Mann-Whitney 
test when appropriate. Intergroup comparisons between RMS values 
were evaluated using the Kruskal-Wallis test, followed by Dunn’s test 
to identify possible differences. A significance level of p < 0.05 was 
set for all analyses.
Ethical considerations
This study was approved by the Research Ethics Committee of 
the State University of Piauí, under protocol no. 120/08.
The LG presented with pain (∆ = 5.0; p = 0.0001), while altered 
sensitivity was diagnosed in 24 subjects (82.8%). The control group 
(CG) did not exhibit these altered characteristics.
Figure 1 presents the prevalence of grade 1 and 2 disability in 
the LG. A higher prevalence of individuals with grade 2 disability 
was found in the LG (∆ = 75.9%; p = 0.0001), with no statistically 
significant difference between sexes.
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FIGURE 1 - Prevalence of the degree of disability in the leprosy group.
*p < 0.05; degree 1 versus degree 2.
FIGURE 2 - Comparative analysis of the extension strength of the right (RH) and left (LH) 
extensor hallucis longus muscles and right (RD) and left (LD) dorsiflexion in the leprosy (LG) 
and control (CG) groups.
*p < 0.05; LG versus CG.
FIGURE 3 - Comparative electromyographic analysis using root mean square values during right 
(RMSR) and left (RMSL) dorsiflexion in the leprosy (LG) and control (CG) groups.
*p < 0.05; LG versus CG.
Figure 2 displays the comparisons between 
the extension strength of the right (RH) and left 
(LH) extensor hallucis longus muscles as well as 
dorsiflexion of the right (RD) and left (LD) feet 
between the LG and CG. The LG exhibited lower 
extension strength in the right and left extensor 
hallucis longus muscles (∆ = 1.28, p = 0.0001; 
∆ = 1.55, p = 0.0001, respectively) and dorsiflexion 
of the right and left feet (∆ = 1.24, p = 0.0001; 
∆ = 1.45, p = 0.0001, respectively) than the CG for 
both movements and on both sides.
Figure 3 shows the comparison of electro-
myography analyzed using RMS values for right 
(RMSR) and left (RMSL) dorsiflexion in the LG 
and CG. Intragroup comparisons made between the 
right and left sides were not significant. The lowest 
levels of electromyographic signals were found in 
the LG. The RMSR (Δ = 181.66m·s-2, p = 0.001) 
and RMSL (Δ = 102.57m·s-2, p = 0.002) values 
were lower in the LG than in the CG on both sides.
DISCUSSION
The results of this study showed that the 
extension strength of the right (RH) and left 
(LH) extensor hallucis longus muscles and the 
dorsiflexion of the right (RD) and left (LD) feet 
in the LG exhibited no significant intragroup 
differences. The LG had the lowest mean values of 
extension strength and dorsiflexion, which were 
significant when compared with the CG. The same 
occurred with the electromyographic signals using 
RMS values. However, as expected, there was always 
a significant difference in the RMS values between 
the LG and CG, with the smallest RMS values 
obtained in the LG.
These findings were corroborated by Wexler and 
Melchior35, who analyzed the palmar/plantar and 
dorsal sensitivity of 140 leprosy patients using 2-g 
monofilaments. Higher sensitivity was detected in 
the feet, but with no significant differences between 
the right and left sides. The same occurred in the LG.
Strength levels and electromyographic signal 
response were consistent in the LG, demonstrating 
that individuals with leprosy have decreased muscle 
strength due to possible nerve damage caused by the 
leprosy bacillus16,17.
The mean pain levels in the LG were 50% on 
the VAPS scale. The pain experienced in the LG 
may result from chronic inflammation, in which 
there is significant thickening. This is due to nerve 
swelling in osteoligamentous channels, the common 
fibular case, at knee level around the fibular neck 
and posterior tibial nerve in the tarsal tunnel, 
characterizing neuritis36,37.   
The present study observed no gender-based 
differences in the prevalence of disability levels. 
However, the prevalence of disability levels seems 
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